Gold prices just lower; monthly gains on track
Baker Bros. Advisors and related entities reported purchasing shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 30, 2025. The biotechnology company, currently valued at $2.89 billion, has shown strong momentum with a 41% return over the past year. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $53 to $79. The transactions involved the acquisition of 655,500 shares of common stock at a price of $44.00, totaling $28,842,000.
Specifically, 667, L.P. acquired 55,191 shares, while Baker Brothers Life Sciences, L.P. purchased 600,309 shares.
In addition to the common stock, the entities also acquired prefunded warrants, exercisable into Kymera Therapeutics common stock. 667, L.P. acquired 55,191 prefunded warrants and Baker Brothers Life Sciences, L.P. acquired 600,309 prefunded warrants at a price of $43.9999 per warrant.
In other recent news, Kymera Therapeutics has announced a $250 million public stock offering, which includes common stock and pre-funded warrants. The company plans to use the proceeds to advance its degrader programs and for general corporate purposes. This capital raise is significant as it supports the development of Kymera’s pipeline of preclinical and clinical programs. Meanwhile, BofA Securities has raised its price target for Kymera to $54, citing pipeline updates, while H.C. Wainwright increased its target to $60, highlighting the potential of the STAT6 program as a key driver. Brookline Capital Markets, however, lowered its price target to $70 due to changes in revenue timing from collaborations with Sanofi (NASDAQ:SNY). Kymera’s partnership with Gilead Sciences (NASDAQ:GILD) to develop a novel CDK2 degrader also marks a notable business development. Despite the discontinuation of KT-474, Kymera and Sanofi remain committed to advancing KT-485, with clinical trials expected in 2026. These developments underscore Kymera’s ongoing efforts to establish collaborations and optimize its degrader candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.